BioLineRx initiates Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

BioLineRx initiates Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.

BioLineRx initiates Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

Peptide News from Biotech and Pharma, Raw News September 26, 2017

BL-8040 is a short peptide for the treatment of acute myeloid leukemia, solid tumors and certain hematological indications. It functions as a high-affinity ...